Propanc Biopharma

Propanc Biopharma (formerly Propanc Pty Ltd) is a pharmaceutical company which focuses on the development of therapeutics for late-stage metastatic cancers.In December 2021, Propanc Biopharma Inc announced the entering into an equity purchase facility of up to $5 million with Dutchess Capital Growth Fund LP.In March 2020, the company entered into a financing of up to $3 million with an institutional investor, with an initial $450,000 of securities purchased at closing. To complete the the transaction, the company entered into a Securities Purchase Agreement for the purchase of 11,250,000 shares of common stock and prefunded warrants issued at closing and 11,250,000 Series A warrants to purchase common stock at $0.20 per share. At closing, the investor was also issued 63,750,000 Series B warrants to purchase common stock at $0.04 per share (for an aggregate maximum exercise price of $2,550,000), and 63,750,000 Series C warrants to purchase common stock at $0.20 per share, which vest upon exercise